Eli Lilly and Company vs Pfizer Inc.: Strategic Comparison
Key Differences at a Glance
| Field | Eli Lilly and Company | Pfizer Inc. |
|---|---|---|
| Revenue | $65.2B | $62.6B |
| Founded | 1876 | 1849 |
| Employees | 50,000 | 75,000 |
| Market Cap | $1.05T | $148.0B |
| Headquarters | United States | United States |
Quick Stats Comparison
| Metric | Eli Lilly and Company | Pfizer Inc. |
|---|---|---|
| Revenue | $65.2B | $62.6B |
| Founded | 1876 | 1849 |
| Headquarters | Indianapolis, Indiana | New York, New York |
| Market Cap | $1.05T | $148.0B |
| Employees | 50,000 | 75,000 |
Eli Lilly and Company Revenue vs Pfizer Inc. Revenue — Year by Year
| Year | Eli Lilly and Company | Pfizer Inc. | Leader |
|---|---|---|---|
| 2025 | $65.2B | $62.6B | Eli Lilly and Company |
| 2024 | $45.0B | $63.6B | Pfizer Inc. |
| 2023 | $34.1B | $59.6B | Pfizer Inc. |
| 2022 | $28.5B | $101.2B | Pfizer Inc. |
| 2021 | $28.3B | $81.3B | Pfizer Inc. |
Business Model Breakdown
Overview: Eli Lilly and Company vs Pfizer Inc.
This in-depth comparison examines Eli Lilly and Company and Pfizer Inc. across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Eli Lilly and Company on its own, evaluating Pfizer Inc., or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Eli Lilly and Company and Pfizer Inc. is widest.
On the headline numbers, Eli Lilly and Company reports annual revenue of $65.2B against $62.6B for Pfizer Inc., while their respective market capitalizations stand at $1.05T and $148.0B. Eli Lilly and Company is headquartered in United States and Pfizer Inc. operates from United States, and those different home markets shape how each company competes.
Eli Lilly and Company: Lilly has transformed from a broad pharmaceutical company into one of the world's most valuable drugmakers because of its cardiometabolic portfolio and pipeline. The core question is how long demand, capacity, and patent protection can compound.
Pfizer Inc.: Pfizer has repeatedly reinvented itself around new therapeutic waves, from industrial fermentation and penicillin to Lipitor, vaccines, COVID products, and now oncology. The 2025 profile is not a pandemic windfall story; it is a large pharmaceutical company trying to rebuild a durable growth base.
Business Models: How Eli Lilly and Company and Pfizer Inc. Make Money
Eli Lilly and Company and Pfizer Inc. pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Eli Lilly and Company and Pfizer Inc..
Eli Lilly and Company business model: Eli Lilly's business model is characterized by substantial, high-risk R&D bets with binary outcomes. The company funds its extensive pipeline through the lucrative sales of specialized treatments in diabetes, oncology, and immunology. Its current astronomical valuation is entirely dependent on maintaining its duopoly with Novo Nordisk in the GLP-1 (weight loss and diabetes) drug market.
Pfizer Inc. business model: Pfizer operates a prominent, volume-driven biopharmaceutical model. It relies entirely on large scale. The company does not simply rely on slow internal R&D; it operates as a substantial M&A engine, aggressively acquiring smaller biotech firms that have promising drugs, and then using its unparalleled global manufacturing and sales force to maximize the commercial revenue before the patents expire.
Competitive Advantage: Eli Lilly and Company vs Pfizer Inc.
The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Eli Lilly and Company stack up against those of Pfizer Inc..
Eli Lilly and Company competitive advantage: Lilly's advantage comes from high-value intellectual property, clinical-development execution, biologics manufacturing scale, commercial access, and a concentrated portfolio of medicines with large addressable markets.
Pfizer Inc. competitive advantage: Pfizer advantage is scale: global regulatory expertise, manufacturing capacity, clinical development experience, commercial infrastructure, vaccine capabilities, and the ability to acquire or partner for scientific platforms.
Growth Strategy: Where Eli Lilly and Company and Pfizer Inc. Are Headed
Future prospects matter as much as current results. The growth strategies below explain how Eli Lilly and Company and Pfizer Inc. each plan to expand from here.
Eli Lilly and Company growth strategy: Lilly is investing heavily in manufacturing capacity, next-generation obesity and diabetes drugs, oncology, immunology, neuroscience, and external collaborations to extend growth beyond the first tirzepatide wave.
Pfizer Inc. growth strategy: Pfizer growth strategy emphasizes oncology, vaccines, internal medicine, obesity and metabolic research, business development discipline, cost reduction, and global commercial execution. Chris Boshoff became Chief Scientific Officer and President, Research & Development effective January 1, 2025.
Financial Picture: Eli Lilly and Company vs Pfizer Inc.
A closer look at the financial trajectory of Eli Lilly and Company and Pfizer Inc. rounds out the comparison.
Eli Lilly and Company: Lilly reported 2025 revenue of $65.179 billion and net income of $20.640 billion. Revenue rose sharply from $45.043 billion in 2024 as demand for Mounjaro and Zepbound expanded.
Pfizer Inc.: Pfizer reported $62.579 billion of FY2025 revenue, compared with $63.627 billion in FY2024 and $59.553 billion in FY2023. Net income was $7.771 billion in FY2025. Pfizer employed approximately 75,000 people worldwide as of December 31, 2025.
Company-Specific SWOT Notes
Eli Lilly and Company
Lilly's tirzepatide franchise represents one of the most commercially successful pharmaceutical launches in history, with combined Mounjaro and Zepbound revenues of approximately $13.
With more than 50 active molecules in clinical development and approximately $9.
Despite a multi-billion-dollar manufacturing expansion program, Lilly's production capacity for tirzepatide and other injectable biologics has lagged the extraordinary demand generated by commercial launches, resulting in drug shortages that have frustrated pa
While tirzepatide's revenue contribution is a strength in the short term, the concentration of approximately 30 percent of Lilly's total revenues in a single molecule creates significant vulnerability to regulatory, safety, manufacturing, or competitive develo
The development of effective oral GLP-1 and incretin-based therapies represents perhaps the largest single commercial opportunity in pharmaceutical history, as an oral formulation would eliminate the injection barrier that limits the addressable market to pati
The Inflation Reduction Act's Medicare drug price negotiation program, which allows the Centers for Medicare and Medicaid Services to directly negotiate prices for high-expenditure drugs, represents a structural threat to Lilly's revenue model in the United St
Pfizer Inc.
Pfizer has manufacturing, regulatory, clinical, and commercial infrastructure that few competitors can match globally.
Major products face loss of exclusivity and pricing pressure, requiring strong replacement revenue.
The Seagen acquisition gives Pfizer a larger oncology platform and ADC pipeline if clinical and commercial execution succeeds.
Medicare negotiation, generic competition, and failed pipeline readouts can compress revenue and margins.
Head-to-Head Scorecard
| Category | Winner | Why |
|---|---|---|
| Revenue Scale | Eli Lilly and Company | Eli Lilly and Company reports the larger revenue base ($65.2B), which serves as a core operational scale signal. |
| Profitability Potential | Comparable | Both organizations prioritize market penetration or are at equivalent reporting tiers. |
| Company Age | Pfizer Inc. | Founded in 1876 vs 1849. The earlier pioneer typically commands longer historical institutional legacy. |
| Innovation Moat | Pfizer Inc. | Higher aggregate count of major acquisitions and key R&D releases indicates a more active technology absorption velocity. |
| Scale (Employees) | Pfizer Inc. | A significantly larger reported workforce supports enhanced global distribution capability. |
| Market Cap | Eli Lilly and Company | Higher public valuation denotes greater forward-looking investor conviction in earnings potential. |
| Future Outlook | Tied | Strategic auditing assesses that both maintain defensive leadership vectors within their core market clusters. |
Who Wins Each Category?
Eli Lilly and Company reports the larger revenue base ($65.2B), which serves as a core operational scale signal.
Both organizations prioritize market penetration or are at equivalent reporting tiers.
Founded in 1876 vs 1849. The earlier pioneer typically commands longer historical institutional legacy.
Higher aggregate count of major acquisitions and key R&D releases indicates a more active technology absorption velocity.
A significantly larger reported workforce supports enhanced global distribution capability.
Who Wins: Eli Lilly and Company or Pfizer Inc.?
Reviewed by Swet Parvadiya, May 2026 - Author Profile
Our analysts compile business strategy profiles from public financial filings, press releases, and analyst reports. Each profile is reviewed for accuracy before publication by our editorial desk and updated on a rolling basis.
Frequently Asked Questions: Eli Lilly and Company vs Pfizer Inc.
Is Eli Lilly and Company better than Pfizer Inc.?
Verdict: Between Eli Lilly and Company and Pfizer Inc., Eli Lilly and Company is the stronger overall option based on higher annual revenue. The decision still depends on which factors matter most for your needs, but on the weight of the evidence above, Eli Lilly and Company comes out ahead in this Eli Lilly and Company vs Pfizer Inc. comparison.
Who earns more — Eli Lilly and Company or Pfizer Inc.?
Eli Lilly and Company earns more with $65.2B in annual revenue versus Pfizer Inc.'s $62.6B. Eli Lilly and Company leads on total revenue based on latest verified figures.
Which company has higher revenue — Eli Lilly and Company or Pfizer Inc.?
Eli Lilly and Company reported $65.2B, while Pfizer Inc. reported $62.6B. The revenue leader is Eli Lilly and Company based on latest verified figures.
Eli Lilly and Company revenue vs Pfizer Inc. revenue — which is higher?
Eli Lilly and Company revenue: $65.2B. Pfizer Inc. revenue: $62.6B. Eli Lilly and Company has the larger revenue base of the two companies.
Sources & References
- SEC EDGAR: Eli Lilly and Company Annual Filings (10-K, 8-K)
- Eli Lilly and Company Corporate Website
- Eli Lilly and Company Annual Report 2025 - Revenue and Financial Data
- sec.gov
- data.sec.gov
- investor.lilly.com
- finance.yahoo.com
- SEC EDGAR: Pfizer Inc. Annual Filings (10-K, 8-K)
- Pfizer Inc. Corporate Website
- Pfizer Inc. Annual Report 2025 - Revenue and Financial Data
- sec.gov
- investors.pfizer.com
- pfizer.com
- investors.pfizer.com